(NaturalNews) First came the denials, then - finally - the admission that, yes indeed, some of GlaxoSmithKline's senior Chinese executives broke the law in a $484.8 million cash and sexual favors scandal.Britain'snewspaper reported on July 22 that the mega-drugmaker's head of emerging markets, Abbas Hussain, had been sent to Shanghai in an effort to manage the crisis, where he apologized to Chinese authorities and pledged that his Big Pharma firm would be taking the charges against its personnel "extremely seriously.""Certain senior executives of GSK China who know our systems well appear to have acted outside of our processes and controls which breaches Chinese law," said Hussain, who is the brother of England cricketer Nasser Hussain. "We have zero tolerance for any behavior of this nature."The company's admission and Hussain's apology came a month after Britain's largest drug manufacturer announced it had found "no evidence of corruption or bribery in our China business," the result of a four-month internal investigation.Though China's public security ministry accepted the apology, the agency nonetheless issued a statement condemning the GSK execs, saying they "violated China's laws and damaged markets by engaging in bribery to raise drug prices, expand sales and reap inappropriate profits."From theIt wasn't clear whether China will execute those involved in this scandal, as the government executed a pair of milk producers for selling more than three million pounds of contaminated milk products in 2009, but we'll keep you posted [ http://www.nytimes.com ].Meanwhile, Chinese authorities moved to detain Peter Humphrey, a British private investigator who has a past association with GSK. "Humphrey, founder and managing director of risk advisory and investigations firm ChinaWhys, was arrested in Shanghai on 10 July," said theOn its website, ChinaWhys notes:The arrest of its Chinese executives is only the latest in a long string of problems GSK has had in China, as evidenced by the fact that the Big Pharma firm conducts as many as 20 internal audits in the country annually. In 2012, more than one-sixth of the 312 personnel fired worldwide for violations of policy were based in China, though the Asian giant only accounts for about 3 percent of GSK's $27 billion annual sales.Thealso reported that the Chinese investigation may also have widened to other Western Big Pharma firms. AstraZeneca announced recently its Shanghai office had also been raided by Chinese police and that one employee had been detained for "questioning."And last year, GSK paid out $3 billion in fines in the U.S. to "settle claims that it tricked and bribed doctors into prescribing dangerous antidepressants to children," the paper said.